Adherence and long-term outcomes of therapy in paediatric patients in Greece using the easypod™ electromechanical device for growth hormone treatment: The phase IV multicentre easypod™ connect observational study (ECOS).

Plain-language guide to PMID 32739654 (2021): open-label and multicenter phase 4 clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 32739654
Journal: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
Year: 2021
Study type: Clinical Trial, Phase IV
Authors: Charmandari E et al. (7 authors)
DOI: 10.1016/j.ghir.2020.101336
Registered trial: NCT01363674

What This Study Did, in Plain Language

What Was Tested

This phase 4 clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

This analysis aimed to evaluate the adherence of Saizen® administered via easypod™ in a cohort of Greek patients from the easypod™ connect observational study (ECOS).

Why It Was Studied

The easypod™ injection device allows automatic recording and transmission of adherence data from patients receiving recombinant human growth hormone (rhGH [Saizen®]) to treat growth disorders.

Who Took Part

PubMed indexes the participants as young children, children and teenagers, both men and women.

How the Study Was Run

The design is described as open-label and multicenter.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Drug Delivery Systems, Electronics, Greece, Growth Disorders, Human Growth Hormone, Longitudinal Studies and Prognosis.

The authors tagged it with the keywords Adherence, Easypod™, Growth hormone deficiency, Paediatric patients, Small for gestational age and Turner syndrome.

What This Means in Plain Language

The paper is an open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.